Targeting Il-12/Il-23 In Crohns Disease

Targeting IL-12/IL-23 in Crohn’s Disease

Targeting the IL-12/23 Pathway in IBD

Understanding the use of IL12/IL23 targeted biologics

New Biologic Therapies that Target the IL-12/23 Pathway

Novel Targets and Therapeutic Perspectives in IBD: Beyond Anti-TNF

Targeting the IL-12/23 Pathway in IBD: Q&A

New Crohn's & Colitis Medications and IBD Treatments on the Horizon

Crohn's & Colitis Foundation

IBD: Safety and Positioning of IL-23 Inhibitors Under Investigation

WATCH NOW! What’s IL-23 Got to Do With It? Targeted Therapies in...

IBD Research and How You Can Take Part

Crohn's & Colitis Foundation

Crohn’s Disease: The Value of Treat-to-Target Therapy

Overcoming Clinical Dilemmas in Crohn’s Disease

IL23 Inhibitors and COVID-19

Crohn's and Colitis Canada

Understanding the mechanisms of action of new agents: Implications for efficacy and safety

Treat to Target in IBD

Clean-Up on IL-23: Integrating the Science of Inflammatory Targets into Treatment Decision-making

Improvements in Targeted IBD Management: Innovative Biologics and Small Molecules

IBD Insider 2023: Patient Updates from Crohn's & Colitis Congress

Crohn's & Colitis Foundation

Positioning of Biologics and New Therapeutics for Crohn's Disease

Disease Monitoring: Implementing the STRIDE II Recommendations

Crohn's & Colitis Foundation